We would love to hear your thoughts about our site and services, please take our survey here.
How on earth was dose escalation "priced in"? They effectively informed the market yesterday that Precision works. If that had happened in 2020 or H1 last year the SP would have rocketed. The reason we didn't rocket yesterday was due to liquidity. Where was all the liquidity going to come from to put a rocket up the SP? The biotech funds suffering massive redemptions? The UK Smaller co's funds aren't awash with inflows. PI's are back at work and have less disposable income to invest. It'll turn again when inflation peaks, M&A begins IMO.
It wasn't a cross ramp RD. I don't hold either. When everyone is scratching their heads wondering wtf is going on with the price action, it's important to have perspective of the wider macro environment. We're all addicted to to following the Avacta story but it's important to view it in context
The issue of great news being sold into isn't unique to AVCT. Have a look at $XBI, which is a S&P listed biotech ETF. It is down c.50% from the 52W high.
Non revenue generating growth stocks are getting hit badly at the moment due to rising interest rates and inflation. Growth stocks are valued based on future cash flow (FCF). If interest rates and inflation are higher then it costs more to realise said FCF. Non revenue generating biotech have this to contend with whilst also having trials delayed due to C19.
Biotech funds are suffering huge redemptions and have to sell something to meet those redemptions. When this is compounded with the same stocks being shorted the **** out of then it's not pretty but it will turn. $PDSB reported strong efficacy data on a P2 this week, spiked and ended the day down! Says it all.
I'm glad AVCT is funded for the foreseeable (assuming no LFT sales, of which I'm certain there will be plenty) as we wouldn't want to be going to the markets to raise right now that's for sure.
Absolutely Investor 110. Obviously bulk sales can be made to businesses as opposed to much smaller sales to individuals and businesses can hand out to their staff to use without professional oversite. This wasn't possible pre HUA. It also links in with Saturn pass, which is aimed at employers.
Yes, probably not Teck. 606 million placing shares to get through? 100m down, 500m to go! On current volume it won't take that long to clear. Assuming all those that took part in the placing are looking to dump immediately.
I've been thinking exactly the same thing Ivor. >14 times average volume yesterday and 4 times average volume traded already today. Obviously there is a huge buyer / buyers mopping up these sells otherwise the SP would have been decimated. It will be interesting to see how the land lies when volume drops back to normal levels. I think we could well see a strong bounce back. We now have the opportunity to add at a lower price than Glencore, Orion et al. and when volume settles down again I will not be looking the gift horse in the mouth
I think that is pessimistic Tornadotony. JM said in the last investor presentation that a Nickel mine producing what Araguia would produce after stage 2 is currently valued at £1.6n. When HZM is producing that in a few years, based on 3.7bn shares in issue, that would equate to 43p per share.
With a, presumably, risking nickel price, the mcap could be even higher. With Vermelho progressing to DFS and HZM having successfully demonstrated their ability to take projects through to production, Vermelho should start to be represented in our valuation. With Vermelho being funded from FCF, HZM should be worth many multiples of where we are today.
Does anyone want to borrow my rose tinted glasses?
The whinging on this BB is pathetic. It's from the same pair of whingers that have been using this BB as a some sort of counselling group for the past few years I might add.
MB has 800k of his own and his family's money invested. He has an incredible track record of delivery having taken previous projects through to production from scoping. If you think financing is taking a while for ACP, try being invested in HZM.
I have always found MB very responsive. If you contact the company, I bet that MB replies within a few days. That would be far more productive than whinging on a BB and it would save the rest of us scrolling through your drivel.
I seem to recall AS saying that Abingdon had manufactured the validation batch. Presumably once validation is complete, we will get an update. Unless it doesn't go well of course, in which case we will get deafening silence again.
Just an after thought re having sufficient samples to meet the aforementioned requirements. Dr S said that Abingdon were producing the validation batch. Presumably we can use the results from the validation batch to increase the sample size. Depending on numbers we could then have sufficient samples to meet the requirement.
LFT's are a mature existing technology. Presumably Toukan is referring to the affirmer platform being unique. The validation procedure that will follow hasn't been determined as far as I can see but I doubt it includes frozen pig samples so it should make it a level playing field. CE marking is self certification but Avacta's is based upon independent clinical validation so I don't think we have anything to worry about and everything to gain. I'm not sure our competitors will be pleased to read that, not least Innova after the FDA debacle.
On a separate note, I particularly liked this extract "The government anticipates that private sector provided testing will form a crucial part of day-to-day testing as we move into the long-term management of COVID-19 and reopen the economy. We therefore expect that this will require considerable expansion of domestic production and potentially an increase in imports to ensure there is sufficient supply to meet demand." HUA and we can attack an underserved market. AS is playing the long game for the long term benefit of the business. Frustrating at times but we'll thank him in the long run.
Thanks for sharing Icecool
DHSC still haven't paid their bills despite accepting the order and using the products. 60 people have lost their jobs as a result of the impact on cash flow yet Innova had no issue getting paid their 3bn. It just gets worse and worse and people get hung up over getting a DHSC contract